AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14) compared ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There was a ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

The purpose of selecting an appropriate inhaler device is to improve patient adherence and inhaler technique to achieve the goals of therapy for patients with COPD. In 2005, the American College ...